Literature DB >> 27742565

The role of perioperative inflammatory-based prognostic systems in patients with colorectal liver metastases undergoing surgery. A cohort study.

Leonardo Solaini1, Bambang T Atmaja1, Prabhu Arumugam1, Robert R Hutchins1, Ajit T Abraham1, Satyajit Bhattacharya1, Hemant M Kocher2.   

Abstract

BACKGROUND: We aim to evaluate the prognostic value of preoperative and postoperative inflammatory systems in patients who had undergone surgery for colorectal liver metastases, focusing our analysis on the role of C-reactive protein-to-albumin ratio (CAR) and Glasgow prognostic score (GPS).
METHODS: A total of 194 patients were enrolled onto this study. Demographics, tumor-related variables, preoperative and postoperative (day 1) inflammatory variables were analyzed as potential prognostic factors.
RESULTS: For the whole cohort three and 5-year survival were 68% and 53% respectively. Median follow up was 27 months (IQR 10-42). At multivariate analysis only preoperative GPS (HR 12.06, 95% CI 2.82-51.53; p = 0.0008) was an independent risk factor for poor survival. Patients with a preoperative GPS = 0 had a 3-years survival of 70% while it was 33% for those with GPS = 1 (p < 0.0001). In patients with preoperative GPS = 0 preoperative CAR (HR 1.19, 95%CI 1.05-1.35; p = 0.0059) could identify a sub-population at risk for reduced survival. The optimal cut-off for preoperative CAR (preCAR) was 0.133 (HR 7.11 95% CI 1.37-36.78, p = 0.0063). 3-years survival was 75% and 21% for patients with preCAR>0.133 and ≤ 0.133, respectively (p = 0.0005). The immediate postoperative inflammatory status did not have a significant impact on survival.
CONCLUSION: GPS is a significant prognostic factor in patients with colorectal liver metastases undergoing surgery. CAR could be a valuable tool to further stratify patients with preoperative GPS = 0 according to their prognosis.
Copyright © 2016 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Albumin; C-reactive protein; Colorectal liver metastasis; Inflammatory-based prognostic system; Survival

Mesh:

Substances:

Year:  2016        PMID: 27742565     DOI: 10.1016/j.ijsu.2016.10.010

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  5 in total

1.  Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort.

Authors:  Andrea Casadei-Gardini; Leonardo Solaini; Laura Riggi; Eleonora Molinaro; Vincenzo Dadduzio; Mario Domenico Rizzato; Antonio Pellino; Luca Faloppi; Giorgia Marisi; Paola Ulivi; Matteo Canale; Giulia Orsi; Giulia Rovesti; Kalliopi Andrikou; Andrea Spallanzani; Fabio Gelsomino; Francesco Giuseppe Foschi; Fabio Conti; Alessandro Cucchetti; Giorgio Ercolani; Paola Biason; Sara Lonardi; Stefano Cascinu; Mario Scartozzi
Journal:  Gastrointest Tumors       Date:  2019-08-20

Review 2.  Biomarkers for Evaluating the Inflammation Status in Patients with Cancer.

Authors:  Ali Guner; Hyoung-Il Kim
Journal:  J Gastric Cancer       Date:  2019-09-09       Impact factor: 3.720

3.  Prognostic value of C-reactive protein to albumin ratio in metastatic colorectal cancer: A systematic review and meta-analysis.

Authors:  Yan Pan; Yinmei Lou; Lin Wang
Journal:  Medicine (Baltimore)       Date:  2021-11-19       Impact factor: 1.889

4.  Host phenotype is associated with reduced survival independent of tumour biology in patients with colorectal liver metastases.

Authors:  David P J van Dijk; Matthew Krill; Farshad Farshidfar; Ting Li; Sander S Rensen; Steven W M Olde Damink; Elijah Dixon; Francis R Sutherland; Chad G Ball; Vera C Mazurak; Vickie E Baracos; Oliver F Bathe
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-10-31       Impact factor: 12.910

Review 5.  Prognostic value of the C-reactive protein to albumin ratio in colorectal cancer: an updated systematic review and meta-analysis.

Authors:  Chun-Kai Liao; Yen-Lin Yu; Yueh-Chen Lin; Yu-Jen Hsu; Yih-Jong Chern; Jy-Ming Chiang; Jeng-Fu You
Journal:  World J Surg Oncol       Date:  2021-05-01       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.